Source: Annual Congress 2009 - Pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Pepke-Zaba, A. Beardsworth, M. Chan, M. Angalakuditi (Cambridge, London, United Kingdom; Toronto, Canada; Indianapolis, United States Of America). Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension. Eur Respir J 2009; 34: Suppl. 53, 1487

Member's Comments

No comment yet.

Related content which might interest you: Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005 Health-related quality of life in patients with pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 608-616 Year: 2011 Measurement of quality of life in pulmonary hypertension and its significance Source: Eur Respir J 2006 Oct 01;28(4):808-815 Year: 2006 Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR Source: Eur Respir J, 57 (2) 2000414; 10.1183/13993003.00414-2020 Year: 2021 Relationship of quality of life and life expectancy with tolerance to physical exercises and cardio respiratory parameters in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013 The effect of pulmonary rehabilitation on health-related quality of life in patients with pulmonary sarcoidosis Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings Year: 2018 emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension Source: Eur Respir J 2014; 43: 1106-1113 Year: 2014 Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study Source: ERJ Open Res, 7 (3) 00617-2020; 10.1183/23120541.00617-2020 Year: 2021 Impact of Sars-CoV-2-Pandemic on mental disorders and quality of life in patients with pulmonary arteriaI hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Assessment of quality of life and social and economic impact of the disease in patients with pulmonary arterial hypertension in Germany – Data of the SANTANA-Study Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Pulmonary arterial hypertension: the burden of disease and impact on quality of life Source: Eur Respir Rev 2015; 24: 621-629 Year: 2015 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Relationship between health-related quality of life and pulmonary function in COPD outpatients Source: Eur Respir J 2002; 20: Suppl. 38, 253s Year: 2002 Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) Source: Eur Respir J 2010; 35: 118-123 Year: 2010